Ani Pharmaceuticals (ANIP) Net Cash Flow (2010 - 2026)

Ani Pharmaceuticals has disclosed Net Cash Flow across 17 years of filings, most recently posting $49.0 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 27.08% year-over-year to $49.0 million; the TTM figure through Jun 2026 stood at $143.0 million (up 739.65% YoY), while the FY2025 annual figure was $141.0 million, up 286.07% from the prior year.
• Net Cash Flow came in at $49.0 million for Q2 2026 at Ani Pharmaceuticals, up from $25.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $94.0 million in Q2 2023 to a low of -$95.0 million in Q3 2024.
• Average Net Cash Flow over 5 years is $14.2 million, with a median of $13.0 million recorded in 2023.
• Year-over-year, Net Cash Flow tumbled 1567.69% in 2022 and jumped 8844.12% in 2025.
• Over 5 years, Net Cash Flow stood at -$8.0 million in 2022, then surged by 448.36% to $28.0 million in 2023, then slumped by 99.03% to $272000.0 in 2024, then jumped by 8844.12% to $24.3 million in 2025, then surged by 101.28% to $49.0 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $49.0 million in Q2 2026, $25.4 million in Q1 2026, and $24.3 million in Q4 2025.